Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This guideline reviews the diagnosis of androgenetic alopecia and offers expert consensus recommendations tailored to males, females, and adolescents, but reports no new clinical results.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This article reviews the discourse around male cosmetic surgery patients and argues against the perception that cosmetic surgery will become as common among men as it is among women.

This study highlights that adverse effects from finasteride may persist in men after discontinuation, indicating a potential "post-finasteride syndrome.

This study found that finasteride significantly reduced symptom severity scores in patients with inflammatory chronic pelvic pain syndrome, though its effect on pain was not significant.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

The authors reported that young men with infertility-related conditions experienced improved seminal quality after stopping finasteride, suggesting potential adverse effects on fertility during treatment.

This study developed a mouse model for radiation cystitis that mimics human pathology and found that radiation exposure leads to increased urinary frequency and long-term weakening of urothelial integrity.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This review discusses factors affecting fertility in both men and women with congenital adrenal hyperplasia and emphasizes individualized preconception management but reports no new clinical results.

This case report suggests a possible association between long-term finasteride use for male pattern baldness and the development of cataracts and intraoperative floppy-iris syndrome in a patient.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This review describes current medical and surgical treatments for transgender men, highlighting the effectiveness and general tolerability of hormone treatment, and suggesting that surgical benefits often surpass associated risks, although it reports no new clinical findings.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

This review discusses the dermatologic care of transgender individuals and highlights the need for more quantitative research to improve clinical understanding and support future studies.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This study concluded that 5α-reductase inhibitors were associated with improved survival in men with bladder cancer, while α-blockers showed no effect.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This study described four cases of delayed diagnosis of Cushing’s syndrome, highlighting that increased clinical awareness and screening could reduce its associated morbidity and mortality.

This review discusses the management options for recurrent ischemic priapism, noting that ketoconazole, finasteride, and other hormonal therapies may be effective but can have significant side effects; it reports no new clinical findings.

This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.

This review discusses the prevalence and etiologies of sexual dysfunction in young men, highlighting the increased recognition of organic causes alongside psychosomatic factors, and reports no new clinical results.

This paper discusses the adverse effects of finasteride, including sexual dysfunction and depression, and suggests that treatment customization based on individual factors like hand preference and sexual orientation could improve outcomes and reduce these side effects.